托吡酯联合碳酸锂治疗急性躁狂症
Topiramate Add-on Lithium Carbonate for Treatment of Acute Mania.
作者信息
Mirsepassi Zahra, Mazinani Robabeh, Fadai Farbod, Alibeigi Neda, Nazeri Astaneh Ali
机构信息
Resident, Department of Psychiatry, Razi Psychiatric Hospital, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Psychiatrist, Associate Professor, Department of Psychiatry, Razi Psychiatric Hospital, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
出版信息
Iran J Psychiatry Behav Sci. 2013 Fall;7(2):11-5.
OBJECTIVE
The purpose of this study was to evaluate the effect of adjunctive topiramate in treating acute mania.
METHODS
In this study which was a double-blinded randomized clinical trial, 46 bipolar patients in manic episode, were treated with lithium carbonate and topiramate versus lithium carbonate and placebo and treatment responses were assessed by Young Mania Rating Scale (YMRS) weekly.
RESULTS
In both intervention and control groups, YMRS score had significant decline after 8 weeks(p < 0.001), but there was no statistically significant difference between the two groups (p = 0.419). The highest score decline was after two weeks. YMRS score at baseline did not have statistically significant difference between the intervention and control groups (p = 0.709).
CONCLUSIONS
This study failed to show antimanic efficacy of adjunctive topiramate in the treatment of those with acute manic.
DECLARATION OF INTEREST
None.
CLINICAL TRIAL REGISTRATION
目的
本研究旨在评估托吡酯辅助治疗急性躁狂的效果。
方法
本研究为双盲随机临床试验，46例双相情感障碍躁狂发作患者，分别接受碳酸锂联合托吡酯治疗与碳酸锂联合安慰剂治疗，每周采用青年躁狂评定量表（YMRS）评估治疗反应。
结果
干预组和对照组在8周后YMRS评分均显著下降（p<0.001），但两组间无统计学显著差异（p = 0.419）。评分下降最多发生在两周后。干预组和对照组基线时的YMRS评分无统计学显著差异（p = 0.709）。
结论
本研究未能显示托吡酯辅助治疗对急性躁狂患者的抗躁狂疗效。
利益声明
无。
Zotero 插件